Generative AI Enters patient care: EPFL-Developed Meditron Undergoes First Clinical Trial at CHUV
Lausanne, Switzerland – In a landmark progress for healthcare technology, the Centre Hospitalier Universitaire Vaudois (CHUV) in Lausanne has initiated the first clinical trial utilizing Meditron, a large language model (LLM) designed to assist medical professionals. The trial marks a pivotal step toward integrating generative artificial intelligence directly into patient care workflows.
Developed in 2023 by the Federal Polytechnic School of Lausanne (EPFL), Meditron aims to support clinicians in their decision-making process. This trial at CHUV represents a crucial validation phase, assessing the LLM’s ability to enhance diagnostic accuracy, streamline information access, and ultimately improve patient outcomes.The increasing demands on healthcare systems, coupled with the exponential growth of medical literature, necessitate innovative tools like meditron to help doctors stay abreast of the latest research and provide optimal care.
Originally launched in 7B and 70B parameter versions, Meditron is built upon Meta’s Llama 2 and specifically adapted for the medical domain. Its training leveraged peer-reviewed scientific literature from open access databases,ensuring a foundation of credible and validated information. The CHUV trial will evaluate Meditron’s performance in real-world clinical scenarios, focusing on its ability to synthesize complex medical data and offer relevant insights to physicians.
Researchers will closely monitor the AI’s outputs, comparing its suggestions to established medical protocols and expert opinions. The results of this trial are expected to inform future development and deployment strategies for Meditron and similar AI-powered tools, potentially revolutionizing how healthcare is delivered.
